Nicholas DeVito
Overview:
I am an instructor of Medical Oncology who primarily treats patients with gastrointestinal malignancies. My laboratory and translational research is focused on tumor immune evasion and immunotherapy, with a specific interest in dendritic cell tolerance.
Positions:
Assistant Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
M.D. 2012
University of South Florida, College of Medicine
Internal Medicine Internship and Residency
Tufts University School of Medicine
Hematology-Oncology Fellowship, Medicine
Duke University School of Medicine
Grants:
Expanded access use of MRTX849 for the treatment of patients with advanced solid tumors with a KRAS G12C mutation
Administered By
Duke Cancer Institute
Awarded By
Mirati Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date
Publications:
Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use.
<jats:p> e18834 </jats:p><jats:p> Background: A growing number of genomic alterations inform treatment of advanced/metastatic colorectal cancer (mCRC). However, use of comprehensive genomic profiling (CGP) is limited in the first-line (1L) setting. Based on the Tempus xT next-generation sequencing assay, we estimated the impact of expanded 1L CGP on the detection of currently actionable alterations in mCRC and associated diagnostic testing costs in a modeled US health plan setting. Methods: A decision analytic model was used to compare testing scenarios over a two-year time horizon: current 1L testing with a mix of CGP and non-CGP diagnostics vs. replacing 20% of usual testing with Tempus CGP. The incidence of 1L mCRC, current testing rates, prevalence of actionable alterations, and test sensitivity were drawn from a literature review and clinical expert input. Currently actionable alterations included KRAS, NRAS, RAF, BRAF, dMMR/MSI, NTRK, RET, EGFR, HER2, MET, PIK3CA and POLE1. Cost components included initial and repeat testing, physician-associated and administrative costs. Opportunities for genomically-informed therapy or clinical trials were assessed under each testing scenario. A forward looking scenario, with additional informative alterations, was also explored. Results: In a hypothetical five million-member health plan, with 50% Medicare and 50% commercial insurance, 1,112 incident cases of mCRC (22 per 100,000 patients) are expected in a typical year. Among these cases, 566 (51%) are expected to undergo 1L molecular diagnostic testing, with 55 projected to undergo repeat testing upon progression within the next year. Based on current real-world testing rates, there are an expected 521 missed opportunities for genomically informed treatment (47% of the incident mCRC population), with 442 missed due to lack of testing and 79 due to testing without CGP. Replacing 20% of usual testing with Tempus CGP in the modeled scenario was associated with up to a $0.003 per member per month (PMPM) testing cost increase and an additional 15.5 patients with an opportunity for genomically-informed care (12.7 patients for guideline-recommended treatment and 2.8 for a clinical trial). The number needed to test (NNT) with Tempus CGP versus the usual mix of testing was 7.8 1L patients to identify one actionable alteration. Scenario analyses projecting the advent of additional genomically-informed treatments and clinical trials resulted in smaller numbers needed to test. Conclusions: Replacing 20% of usual testing with Tempus CGP is associated with a small incremental testing cost but can identify actionable alterations for a meaningful number of patients. For every eight 1L mCRC patients tested with Tempus CGP rather than the usual mix of molecular testing, one additional patient is expected to be identified as having currently actionable alterations. </jats:p>
Authors
Proudman, D; DeVito, NC; Belinson, S; Alsaraf Allo, M; Morris, ED; Signorovitch, J; Patel, AK
MLA Citation
Proudman, David, et al. “Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use.” Journal of Clinical Oncology, vol. 39, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2021, pp. e18834–e18834. Crossref, doi:10.1200/jco.2021.39.15_suppl.e18834.
URI
https://scholars.duke.edu/individual/pub1576026
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
39
Published Date
Start Page
e18834
End Page
e18834
DOI
10.1200/jco.2021.39.15_suppl.e18834
A pilot study evaluating the safety and impact of pretreatment with metformin on colorectal cancer stem cells (CCSC) in patients undergoing resection.
Authors
DeVito, NC; Goodman, MD; Caplain, J; Rajagopal, S; Popowich, D; Orkin, BA; Grimm, E; Tsichlis, PN; Martell, RE; Saif, WM
MLA Citation
DeVito, Nicholas C., et al. “A pilot study evaluating the safety and impact of pretreatment with metformin on colorectal cancer stem cells (CCSC) in patients undergoing resection.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. e14581–e14581. Crossref, doi:10.1200/jco.2014.32.15_suppl.e14581.
URI
https://scholars.duke.edu/individual/pub1576028
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
32
Published Date
Start Page
e14581
End Page
e14581
DOI
10.1200/jco.2014.32.15_suppl.e14581
A RETROSPECTIVE STUDY OF PATIENTS WITH MELANOMA BRAIN METASTASES RECEIVING CONCURRENT WHOLE BRAIN RADIATION AND TEMOZOLOMIDE
Authors
DeVito, NC; Yu, M; Chen, R; Pan, E
MLA Citation
DeVito, Nicholas C., et al. “A RETROSPECTIVE STUDY OF PATIENTS WITH MELANOMA BRAIN METASTASES RECEIVING CONCURRENT WHOLE BRAIN RADIATION AND TEMOZOLOMIDE.” Neuro Oncology, vol. 13, 2011, pp. 42–42.
URI
https://scholars.duke.edu/individual/pub1576029
Source
wos-lite
Published In
Neuro Oncology
Volume
13
Published Date
Start Page
42
End Page
42
533 A tumor-lung NLRP3-TLR4 distant signaling axis drives immunotherapy resistance via G-CSF-dependent expansion of circulating PD1<sup>+</sup>PMN-MDSCs
MLA Citation
Theivanthiran, Balamayooran, et al. “533 A tumor-lung NLRP3-TLR4 distant signaling axis drives immunotherapy resistance via G-CSF-dependent expansion of circulating PD1+PMN-MDSCs.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2022. Crossref, doi:10.1136/jitc-2022-sitc2022.0533.
URI
https://scholars.duke.edu/individual/pub1573543
Source
crossref
Published In
Regular and Young Investigator Award Abstracts
Published Date
DOI
10.1136/jitc-2022-sitc2022.0533
22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients
Authors
MLA Citation
Haykal, Tarek, et al. “22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2022. Crossref, doi:10.1136/jitc-2022-sitc2022.0022.
URI
https://scholars.duke.edu/individual/pub1573544
Source
crossref
Published In
Regular and Young Investigator Award Abstracts
Published Date
DOI
10.1136/jitc-2022-sitc2022.0022

Assistant Professor of Medicine
Contact:
DUMC Box 3052, Durham, NC 27710
Seeley G Mudd Bldg Room 471B, 10 Bryan Searle Drive, Durham, NC 27710